Related Experiment Video
Updated: Aug 29, 2026
Recombinant Collagen I Peptide Microcarriers for Cell Expansion and Their Potential Use As Cell Delivery System in a Bioreactor Model
Published on: February 7, 2018
In vitro release of mitomycin C from collagen implants
C Zimmerman1, J Drewe, J Flammer
1Department of Clinical Pharmacology, University Hospital, Basel, Switzerland.
Purpose:
To study Mitomycin C Loaded Collagen Implant (CI) pharmacokinetics behaviour in vitro.
Methods:
The CI were incubated for 15 minutes in different MMC loading solutions with the following concentrations: 0.03 mg/mL (n = 9), 0.3 mg/mL (n = 10) and 3.0 mg/mL (n = 10). The loaded CI were transferred in 100 micro L of 0.9% NaCl. Aqueous flow of 5 micro L/min was simulated. The MMC concentrations of the samples were determined by high performance liquid chromatography (HPLC). Dissolution kinetics were evaluated by a first-order process. The half-life of dissolution and the time of 95% dissolution were determined.
Results:
The CI absorbed on average a MMC dose of 0.054, 0.530 and 6.090 micro g when incubated in the different MMC loading solutions containing 0.03 mg/mL, 0.3 mg/mL, 3.0 mg/mL of MMC, respectively. In the release experiments, the mean total dose delivered by CI was 0.0493, 0.585 and 5.291 micro g. A linear correlation between loading concentration and the estimated total dose released was demonstrated. The kinetic parameters showed a fast MMC dissolution. The half-life of the 3 series was 8.8, 10.1 and 10.5 min.
Conclusions:
Commercially available CI can be loaded with MMC, and could provide relatively slower release than sponge delivery of MMC. Clinical implications of these results warrants further studies.
Insights
Commercially available collagen implants (CI) can be loaded with Mitomycin C (MMC). These implants demonstrate fast MMC dissolution, offering potentially slower release than sponges for further clinical study.
Area of Science:
- Biomaterials Science
- Pharmacokinetics
- Drug Delivery Systems
Background:
- Mitomycin C (MMC) is an important chemotherapeutic agent.
- Collagen implants (CI) are utilized in various medical applications.
- Understanding the in vitro release kinetics of drugs from CI is crucial for optimizing therapeutic outcomes.
Purpose of the Study:
- To investigate the in vitro pharmacokinetics of Mitomycin C (MMC) loaded into collagen implants (CI).
- To quantify MMC absorption and release from CI under simulated physiological conditions.
- To evaluate the dissolution kinetics and half-life of MMC released from CI.
Main Methods:
- Collagen implants (CI) were incubated in varying concentrations of Mitomycin C (MMC) solutions.
- MMC-loaded CI were subjected to simulated aqueous flow.
- MMC concentrations in released samples were quantified using high-performance liquid chromatography (HPLC).
- Dissolution kinetics were analyzed using a first-order process model.
Main Results:
- A linear correlation was observed between MMC loading concentration and the total dose released from CI.
- The mean total dose delivered by CI ranged from 0.0493 to 5.291 μg, depending on initial loading.
- MMC dissolution from CI exhibited fast kinetics, with half-lives ranging from 8.8 to 10.5 minutes.
Conclusions:
- Commercially available collagen implants (CI) can be effectively loaded with Mitomycin C (MMC).
- CI demonstrate potential for providing a relatively slower release of MMC compared to traditional sponge delivery methods.
- Further clinical studies are warranted to explore the therapeutic implications of MMC-loaded CI.
